You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

CLINICAL TRIALS PROFILE FOR TENOFOVIR ALAFENAMIDE FUMARATE

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for TENOFOVIR ALAFENAMIDE FUMARATE

Subscribe to access the full database, or Subscribe
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00036634 ↗	A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients	Completed	Gilead Sciences	Phase 1/Phase 2	2002-03-01	This study evaluated two doses of tenofovir alafenamide versus tenofovir disoproxil fumarate (tenofovir DF).
NCT01497899 ↗	Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults	Completed	Gilead Sciences	Phase 2	2011-12-28	The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya®; E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (Stribild®; E/C/F/TDF) FDC in HIV-1 infected, antiretroviral treatment-naive adults.
NCT01565850 ↗	D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults	Completed	Gilead Sciences	Phase 2	2012-04-01	This study is to evaluate the safety and efficacy darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination (FDC) tablet versus darunavir (DRV)+cobicistat (COBI)+emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) in HIV-1 infected, antiretroviral treatment-naive adults as determined by the achievement of HIV-1 RNA < 50 copies/mL at Week 24.
NCT01780506 ↗	Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults	Completed	Gilead Sciences	Phase 3	2012-12-26	The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) FDC in HIV-1 positive, antiretroviral treatment-naive adults.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for TENOFOVIR ALAFENAMIDE FUMARATE

Condition Name

Chart
Table

Condition Name for TENOFOVIR ALAFENAMIDE FUMARATE
Intervention	Trials
HIV	14
Chronic Hepatitis b	12
HIV Infections	10
HIV-1 Infection	9
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for TENOFOVIR ALAFENAMIDE FUMARATE
Intervention	Trials
Hepatitis B	30
Hepatitis	26
HIV Infections	20
Hepatitis B, Chronic	19
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for TENOFOVIR ALAFENAMIDE FUMARATE

Trials by Country

Map
Table

Trials by Country for TENOFOVIR ALAFENAMIDE FUMARATE
Location	Trials
United States	373
China	75
Canada	54
United Kingdom	23
France	22
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for TENOFOVIR ALAFENAMIDE FUMARATE
Location	Trials
California	26
Florida	21
Texas	19
New York	19
Michigan	18
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for TENOFOVIR ALAFENAMIDE FUMARATE

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for TENOFOVIR ALAFENAMIDE FUMARATE
Clinical Trial Phase	Trials
Phase 4	22
Phase 3	28
Phase 2	11
[disabled in preview]	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for TENOFOVIR ALAFENAMIDE FUMARATE
Clinical Trial Phase	Trials
Completed	31
Recruiting	24
Not yet recruiting	14
[disabled in preview]	9
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for TENOFOVIR ALAFENAMIDE FUMARATE

Sponsor Name

Chart
Table

Sponsor Name for TENOFOVIR ALAFENAMIDE FUMARATE
Sponsor	Trials
Gilead Sciences	35
Third Affiliated Hospital, Sun Yat-Sen University	5
National Institute of Allergy and Infectious Diseases (NIAID)	4
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for TENOFOVIR ALAFENAMIDE FUMARATE
Sponsor	Trials
Other	83
Industry	45
NIH	5
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.